Indoco Remedies Limited (IN:INDOCO)
:INDOCO
Want to see IN:INDOCO full AI Analyst Report?
INDOCO Stock Chart & Stats
₹228.35
-₹0.55(-0.16%)
At close: 4:00 PM EST
₹228.35
-₹0.55(-0.16%)
Day’s Range― - ―
52-Week Range₹163.70 - ₹348.10
Previous CloseN/A
Volume47.33K
Average Volume (3M)38.33K
Market Cap
₹20.10B
Enterprise Value₹30.09B
Total Cash (Recent Filing)₹231.50M
Total Debt (Recent Filing)₹9.99B
Price to Earnings (P/E)―
Beta1.15
Next Earnings
May 26, 2026EPS Estimate
-3.55Next Dividend Ex-DateN/A
Dividend Yield0.08%
Share Statistics
EPS (TTM)-3.20
Shares Outstanding92,303,604
10 Day Avg. Volume7,145
30 Day Avg. Volume38,334
Financial Highlights & Ratios
PEG Ratio0.16
Price to Book (P/B)2.05
Price to Sales (P/S)1.26
P/FCF Ratio-6.38
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)9
Revenue Forecast (FY)₹20.48B
Bulls Say, Bears Say
Bulls Say
Diversified Revenue StreamsIndoco's mix of formulations, API sales and contract development/manufacturing spreads revenue across product types and channels. This diversification reduces reliance on any single market or product, supporting steadier cash flows and resilience to therapeutic- or region-specific shocks over months.
In-house Manufacturing & R&DOwning manufacturing and R&D capabilities provides control over quality, faster product development and regulatory readiness. Over a 2-6 month horizon, these capabilities enable faster launches, better margin capture and fewer supply disruptions versus asset-light peers, strengthening competitive positioning.
Stable Equity RatioA stable equity ratio implies retained capitalization despite stress, offering a buffer against shocks and supporting credit access. This moderate stability can preserve capacity for incremental investment or refinancing over the medium term, helping maintain operations and strategic initiatives.
Bears Say
Declining Revenue & Negative ProfitabilityFalling revenue coupled with negative net income and margins indicates weakened demand, pricing pressure or cost escalation. Sustained unprofitability erodes retained earnings and competitiveness, limiting reinvestment in products and markets and risking market-share losses over the coming months.
Negative Free Cash FlowNegative free cash flow and deteriorating cash conversion constrain the firm's ability to fund R&D, capex or working capital internally. Over a medium horizon this raises dependence on external financing, increases refinancing risk and can force cuts to strategic investments or product launches.
Rising Financial LeverageIncreased leverage raises interest burdens and reduces financial flexibility. In a volatile generics and specialty market, higher debt elevates covenant and liquidity risks, limiting ability to pursue M&A or tolerate cyclical downturns and potentially forcing defensive measures that harm long-term growth.
Indoco Remedies Limited News
INDOCO FAQ
What was Indoco Remedies Limited’s price range in the past 12 months?
Indoco Remedies Limited lowest stock price was ₹163.70 and its highest was ₹348.10 in the past 12 months.
What is Indoco Remedies Limited’s market cap?
Indoco Remedies Limited’s market cap is ₹20.10B.
When is Indoco Remedies Limited’s upcoming earnings report date?
Indoco Remedies Limited’s upcoming earnings report date is May 26, 2026 which is in 37 days.
How were Indoco Remedies Limited’s earnings last quarter?
Indoco Remedies Limited released its earnings results on Feb 03, 2026. The company reported -₹3.2 earnings per share for the quarter, missing the consensus estimate of -₹2.55 by -₹0.65.
Is Indoco Remedies Limited overvalued?
According to Wall Street analysts Indoco Remedies Limited’s price is currently Overvalued.
Does Indoco Remedies Limited pay dividends?
Indoco Remedies Limited pays a Annually dividend of ₹0.2 which represents an annual dividend yield of 0.08%. See more information on Indoco Remedies Limited dividends here
What is Indoco Remedies Limited’s EPS estimate?
Indoco Remedies Limited’s EPS estimate is -3.55.
How many shares outstanding does Indoco Remedies Limited have?
Indoco Remedies Limited has 92,303,604 shares outstanding.
What happened to Indoco Remedies Limited’s price movement after its last earnings report?
Indoco Remedies Limited reported an EPS of -₹3.2 in its last earnings report, missing expectations of -₹2.55. Following the earnings report the stock price went up 11.011%.
Which hedge fund is a major shareholder of Indoco Remedies Limited?
Currently, no hedge funds are holding shares in IN:INDOCO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Indoco Remedies Limited
Indoco Remedies Limited manufactures and sells formulations and active pharmaceutical ingredients in India and internationally. The company offers respiratory products, such as Karvol Plus, Febrex Plus, and Tuspel; stomatologicals products that include Sensodent-K, Sensoform Toothpaste, Sensoform Gum Paint, Rexidin M, Rexidin SRS, RR Sensoform Dental, Snowdent, Kidodent, Rexidin Plus, and Dentogel; gastrointestinal products, such as Carmicide, Cyclopam, Cyclomeff, and Nosic; pain/analgesics products that include Lignox and T-lac; and ophthal/otologicals products, such as Renolen, Homide, Dexoren S, Zincoren, Otorex, Mofloren-D, and Mofloren LP. It also provides vitamins/minerals/nutrients that include Methycal, Cital UTI, SM Fibro, Cal Aid, SM Fibro, MCBM DHA, and Apispur; urology products, such as Carmicide and Cital; Cloben G and Scabex for dermatology; ATM for anti-infectives; Hemsyl for blood related; MCBM 69 and D Chiro for gynecological; and Spear for anti-haemorrhoidal. In addition, the company provides analytical services, such as impurity profile, particle size analysis, heavy metal analysis, polymorphism and compatibility studies, extractables and leachables studies, lyophilization studies, reference and working standards, forced degradation studies, and chromatographic method development and validation services. Further, it offers services that include architectural design, lighting, mechanical and utility engineering, project and construction management, electrical, control system, piping, structural design, data transfer system, and process engineering. The company serves general practitioners, pediatricians, consultant physicians, dentists, cardiologists, diabetologists, endocrinologists, gynaecologists, and ophthalmologists. The company was formerly known as Indo Continental Trading Company. Indoco Remedies Limited was founded in 1945 and is based in Mumbai, India.
Technical Analysis
Alembic Pharmaceuticals Limited
―
Hikal Limited
―
Morepen Laboratories Limited
―
Solara Active Pharma Sciences Ltd.
―
Unichem Laboratories Limited
―